Search

Meeting Coverage:

Association for Research in Vision & Ophthalmology

ARVO: 2018

Real-World Outcomes of nAMD Treated With Anti-VEGF Therapy

Thomas A. Ciulla, MD, MBA

Show Description +

Thomas A. Ciulla, MD, details a study that examined change of visual acuity versus frequency of anti-VEGF injections over 1 year in patients with neovascular age-related macular degeneration (nAMD). Dr. Ciulla points out key lessons that this study demonstrates.

Posted: 5/03/2018

Keywords:

Anti-VEGF

•

Neovascular Age-Related Macular Degeneration

Up Next

Results From the STOMP-CSC Trial

Results From the STOMP-CSC Trial

Roger A. Goldberg, MD, MBA

Five-Year Rates of Diabetic Retinopathy Progression

Five-Year Rates of Diabetic Retinopathy Progression

Andrew A. Moshfeghi, MD, MBA

A New Approach to Managing Macular Holes?

A New Approach to Managing Macular Holes?

Daniel Su, MD

A Future Role in Retina for Stem Cell and Gene Therapy?

A Future Role in Retina for Stem Cell and Gene Therapy?

Baruch D. Kuppermann, MD, PhD, Nathan C. Steinle, MD

Predictive Data From the HAWK and HARRIER Studies

Predictive Data From the HAWK and HARRIER Studies

A New Approach to Deviation Mapping for Retinal Perfusion

A New Approach to Deviation Mapping for Retinal Perfusion

Richard B. Rosen, MD

Early Experiences and Outcomes With Pneumatic Retinopexy vs. Future Use

Early Experiences and Outcomes With Pneumatic Retinopexy vs. Future Use

Glenn C. Yiu, MD, PhD

Baseline Features and Treatment Outcomes in Wet AMD

Baseline Features and Treatment Outcomes in Wet AMD

Nathan C. Steinle, MD

Digital Disruptions in Ophthalmology

Digital Disruptions in Ophthalmology

John B. Miller, MD, Roger A. Goldberg, MD, MBA

Getting Better at Treating Diabetic Retinopathy

Getting Better at Treating Diabetic Retinopathy

Nadia K. Waheed, MD, MPH, William F. Mieler, MD

DME Treatment Patterns

DME Treatment Patterns

Jeffrey R. Willis, MD, PhD

Quarterly Dosing and AMD: A Cross-Trial Comparison

Quarterly Dosing and AMD: A Cross-Trial Comparison

David A. Eichenbaum, MD

Real-World Outcomes of nAMD Treated With Anti-VEGF Therapy

Real-World Outcomes of nAMD Treated With Anti-VEGF Therapy

Thomas A. Ciulla, MD, MBA

Back to All Videos

Real-World Outcomes of nAMD Treated With Anti-VEGF Therapy

Thomas A. Ciulla, MD, MBA

Thomas A. Ciulla, MD, details a study that examined change of visual acuity versus frequency of anti-VEGF injections over 1 year in patients with neovascular age-related macular degeneration (nAMD). Dr. Ciulla points out key lessons that this study demonstrates.

Posted: 5/03/2018

Keywords:

Anti-VEGF

•

Neovascular Age-Related Macular Degeneration

Please log in to leave a comment.

More From ARVO: 2018 Coverage

Results From the STOMP-CSC Trial

Results From the STOMP-CSC Trial

Roger A. Goldberg, MD, MBA

Five-Year Rates of Diabetic Retinopathy Progression

Five-Year Rates of Diabetic Retinopathy Progression

Andrew A. Moshfeghi, MD, MBA

A New Approach to Managing Macular Holes?

A New Approach to Managing Macular Holes?

Daniel Su, MD

A Future Role in Retina for Stem Cell and Gene Therapy?

A Future Role in Retina for Stem Cell and Gene Therapy?

Baruch D. Kuppermann, MD, PhD, Nathan C. Steinle, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2018.